Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.63 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889995 | 1.00 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3HTR6NOS3 | |
| Hydrochloric Acid SCHEMBL2891904 | 0.99 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3HTR6NOS3 | |
| SCHEMBL8207336 | 0.88 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3HTR6NOS3 | |
| SCHEMBL3423701 | 0.78 | SLC6A3 (0.66) | SLC6A4SLC6A2SLC6A3HTR6NOS3 | |
| SCHEMBL1021448 | 0.78 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3HTR6NOS3 | |
| SCHEMBL1021447 | 0.78 | SLC6A2 (0.62) | SLC6A4SLC6A2SLC6A3HTR6NOS3 | |
| SCHEMBL1020817 | 0.78 | SLC6A2 (0.69) | SLC6A4SLC6A2SLC6A3HTR6NOS3 | |
| SCHEMBL5829586 | 0.78 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3HTR6NOS3 | |
| SCHEMBL5829683 | 0.78 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3HTR6NOS3 | |
| SCHEMBL1020818 | 0.78 | SLC6A2 (0.69) | SLC6A4SLC6A2SLC6A3HTR6NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286193-A1 | Novel Azabicyclo[3.2.1]Oct-2-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2010-11-11 | — | — | US | claimed |
| EP-1937261-B1 | NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-03-03 | — | — | EP | claimed |
| EP-1937261-A1 | NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-07-02 | — | — | EP | claimed |
| WO-2007025978-A1 | NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-08 | — | — | WO | claimed |
| US-20100286193-A1 | Novel Azabicyclo[3.2.1]Oct-2-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2010-11-11 | — | — | US | disclosed |
| EP-1937261-B1 | NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-03-03 | — | — | EP | disclosed |
| EP-1937261-A1 | NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007025978-A1 | NOVEL AZABICYCLO[3.2.1]OCT-2-ENE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286193-A1 | Novel Azabicyclo[3.2.1]Oct-2-Ene Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC6A2, SLC18A2, SLC18A3 | SLC6A4 6/4885SLC6A2 1/4885SLC6A3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.